Abstract
Large-cell neuroendocrine carcinoma (LCNEC) of the lung is a high-grade carcinoma. It is a very rare tumor, approximately 3% of all lung malignancies. Despite LCNEC responds to cisplatin-based chemotherapy prognosis remains poor. We try to identify positive cases for EGFR mutations and ALK rearrangement by using fluorescence in situ hybridization (FISH) as gold standard and its correlation with immunohistochemistry (IHC) in LCNEC aiming to find new therapeutic options for those patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
